middle.news
PYC Therapeutics Unveils Early Clinical Promise for RNA Therapies in Childhood Blindness
9:38am on Monday 4th of May, 2026 AEST
•
Healthcare
Read Story
PYC Therapeutics Unveils Early Clinical Promise for RNA Therapies in Childhood Blindness
9:38am on Monday 4th of May, 2026 AEST
Key Points
PYC-001 shows safety and visual acuity improvements in ADOA patients
VP-001 demonstrates meaningful gains in low-luminance visual acuity for RP11
Both candidates are first-in-indication RNA therapies for untreatable childhood blindness
Phase 1b and Phase 2 studies underway to confirm clinical benefit
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PYC Therapeutics (ASX:PYC)
OPEN ARTICLE